The online version of this article (https://doi.org/10.1007/s11136-018-2025-y) contains supplementary material, which is available to authorized users.
Pyruvate kinase deficiency (PKD) is a rare disease and understanding of its epidemiology and associated burden remains limited. With no current curative therapy, clinical manifestations can be life threatening, clinically managed by maintaining adequate hemoglobin levels through transfusion and subsequent support, but with frequent complications. Treatment goals are to maintain/improve the patient’s quality of life. With new therapies, reliable, valid, and relevant patient-reported outcome (PRO) tools are required for use in clinical trials.
Systematic literature search identified no current PRO tools for capturing/measuring the impact of PKD and treatments in clinical trials. Therefore, the search strategy was revised to consider conditions analogous to PKD in terms of symptoms and impacts that might serve as parallels to the experience in PKD; this included sickle cell anemia, thalassemia, and hemolytic anemia. Psychometric properties, strengths, and weakness of selected appropriate PRO instruments were compared, and recommendations made for choice of PRO tools.
In adult populations, EORTC QLQ C30 and SF-36v2 are recommended, the former being a basic minimum, covering generic HRQoL, and core symptoms such as fatigue. In pediatric populations, PedsQL Generic Core Scale to measure HRQoL and PedsQL MFS scale to measure fatigue are recommended.
Some symptoms/life impacts may be unique to PKD and not observable in analogous conditions. A ‘Physico-Psychosocial Model’ derived from the ‘Medical Model’ is proposed to form the basis for a hypothesized conceptual framework to address the development of PKD-specific PRO instruments.
Supplementary material 1 (PDF 282 KB)11136_2018_2025_MOESM1_ESM.pdf
Grace, R., Zanella, A., Neufeld, E., et al. (2015). Erythrocyte pyruvate kinase deficiency: 2015 status report. American Journal of Hematology, 90(9), 825–830. CrossRef
Beutler, E., & Gelbart, T. (2000). Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood, 95(11), 3585–3588.
Zanella, A., Bianchi, P., & Fermo, E. (2006). Red cell enzyme deficiencies: Molecular and clinical aspects. Haematologica Reports, 2(10), 96–102.
Grace, R., Barcellini, W., Eber, S., et al. (2015). Categorization of clinical severity in pyruvate kinase deficiency (PKD) in an international, observational cohort. In Paper presented at presented at the 20th congress of the European Hematology Association; 11–14 June 2015, Vienna.
Gregg, X., & Prchal, J. (2016). Red blood cell enzymopathies. In R. B. E. Hoffman (Ed.), Hematology: Basic principles and practice (7th ed.). London: Elsevier.
van Wijk, R. (2015). Erythrocyte enzyme disorders. In K. Kaushansky, M. Lichtman, J. Prchal, et al. (Eds.), Williams hematology (9th ed., p. 689). New York: McGraw-Hill.
Zanella, A., & Bianchi, P. (2000). Red cell pyruvate kinase deficiency: From genetics to clinical manifestations. Best Practice & Research: Clinical Haematology, 13(1), 57–81.
Pérez-Albert, P., Guillén, M., Prudencio, M., & Sevilla, J. (2017). Haematopoietic stem cell transplantation in pyruvate kinase deficiency: When is it indicated? Anales de Pediatría, 88(2), 106–107. CrossRef
Morton, D., Knoll, C., Rothman, J., et al. (2015). The clinical features and treatment of iron overload in pyruvate kinase deficiency (PKD): Data from the PKD Natural History Study (NHS). In Paper presented at the 20th congress of the European Hematology Association; 11–14 June 2015, Vienna.
Kung, C., Hixon, J., Kosinski, P., et al. (2017). AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. Blood, 130(11), 1347–1356. CrossRef
Garate, Z., Quintana-Bustamante, O., & Crane, A. (2015). Generation of a high number of healthy erythroid cells from gene-edited pyruvate kinase deficiency patient-specific induced pluripotent stem cells. Stem Cell Reports, 5(6), 1053–1066. CrossRef
Garcia-Gomez, M., Calabria, A., & Garcia-Bravo, M. (2016). Safe and efficient gene therapy for pyruvate kinase deficiency. Molecular Therapy, 24(7), 1187–1198. CrossRef
Meza, N., Alonso, M., Navarro, S., et al. (2007). Development of efficient gene therapy for the treatment of erythrocyte pyruvate kinase deficiency. Blood, 110(11), 2584.
Meza, N., Alonso-Ferrero, M., Navarro, S., et al. (2009). Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. Molecular Therapy, 17(12), 2000–2009. CrossRef
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., & Fusil, F. (2011). Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 467, 318–322. CrossRef
Fucharoen, S., Ketvichit, P., Pootrakul, P., Siritanaratkul, N., Piankijagum, A., & Wasi, P. (2000). Clinical manifestation of beta-thalassemia/hemoglobin E disease. Journal of Pediatric Hematology/Oncology, 22(6), 552–557. CrossRef
Belfield, K., & Tichy, E. (2018). Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. American Journal of Health-System Pharmacy, 75(3), 97–104. CrossRef
Grace, R., Cohen, J., Egan, S., et al. (2018). The burden of disease in pyruvate kinase deficiency: Patients’ perception of the impact on health-related quality of life. European Journal of Haematology.
Worsham, C., Martin, S., Nouraie, S., Cohen, R., & Klings, E. (2017). Clinical and laboratory findings associated with sleep disordered breathing in sickle cell disease. Annals of Hematology, 92(12), E649–E651.
Raghunathan, V., Whitesell, P., & Lim, S. (2018). Sleep-disordered breathing in patients with sickle cell disease. Annals of Hematology, 97(5), 755–762.
Cappellini, M., Musallam, K., & Taher, A. (2009). Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Hemoglobin, 33(Suppl 1), S145–S159. CrossRef
Ballas, S., Zeidan, A., Duong, V., DeVeaux, M., & Heeney, M. (2018). The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review. American Journal of Hematology, 93(7), 943–952. CrossRef
Hilgard, P., & Gerken, G. (2005). Liver cirrhosis as a consequence of iron overload caused by hereditary nonspherocytic hemolytic anemia. World Journal of Gastroenterology, 28(11), 1241–1244. CrossRef
Rossi, F., Perrotta, S., Bellini, G., et al. (2014). Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica, 99(12), 1876–1884. CrossRef
Wang, Y., Liu, W., Masuyama, R., et al. (2012). Pyruvate dehydrogenase kinase 4 induces bone loss at unloading by promoting osteoclastogenesis. Bone, 50(1), 409–419. CrossRef
Matta, B., As, O., Maakaron, J., Koussa, S., Daderian, R., & Taher, A. (2014). Leg ulcers in patients with β-thalassaemia intermedia: A single centre’s experience. Journal of the European Academy of Dermatology and Venereology, 28(9), 1245–1250. CrossRef
Vogiatzi, M., Macklin, E., & Fung, E. (2009). et a. Bone disease in thalassemia: A frequent and still unresolved problem. Journal of Bone and Mineral Research, 24(3), 543–557. CrossRef
Martí-Carvajal, A., Solà, I., & Agreda-Pérez, L. (2016). Treatment for avascular necrosis of bone in people with sickle cell disease. The Cochrane Database of Systematic Reviews, 8, CD004344.
Grace, R. (2015). Pyruvate Kinase Deficiency Natural History Study (PKD NHS) (NCT02053480). Retrieved January 8, 2018, from https://clinicaltrials.gov/ct2/show/record/NCT02053480.
Stegenga, K., Ward-Smith, P., Hinds, P., Routhieaux, J., & Woods, G. (2004). Quality of life among children with sickle cell disease receiving chronic transfusion therapy. Journal of Pediatric Oncology Nursing, 21(4), 207–213. CrossRef
Thomas, V., & Taylor, L. (2002). The psychosocial experience of people with sickle cell disease and its impact on quality of life: Qualitative findings from focus groups. British Journal of Health Psychology, 7(3), 345–363. CrossRef
Abetz, L., Baladi, J., Jones, P., & Rofail, D. (2006). The impact of iron overload and its treatment on quality of life: Results from a literature review. Health and Quality of Life Outcomes, 4, 73–78. CrossRef
Lasch, K., Evans, C., & Schatell, D. (2009). A qualitative analysis of patient-reported symptoms of anemia. Nephrology Nursing Journal, 36(6), 621–624.
McClish, D., Penberthy, L., Bovbjerg, V., et al. (2005). Health related quality of life in sickle cell patients: The PiSCES project. Health and Quality of Life Outcomes, 29(3), 50–56. CrossRef
Dampier, C., Lieff, S., LeBeau, P., et al. (2010). Health-related quality of life in children with sickle cell disease: A report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatric Blood & Cancer, 55(3), 485–494. CrossRef
Ameringer, S., Elswick, R., & Smith, W. (2014). Fatigue in adolescents and young adults with sickle cell disease: Biological and behavioral correlates and health-related quality of life. Journal of Pediatric Oncology Nursing, 31(1), 6–17. CrossRef
Sobota, A., Yamashita, R., Xu, Y., et al. (2011). Quality of life in thalassemia: A comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. American Journal Of Hematology, 86(1), 92–95. CrossRef
Payne, K., Desrosiers, M., Caro, J., et al. (2007). Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion, 47(10), 1820–1829. CrossRef
Payne, K., Rofail, D., Baladi, J., et al. (2008). Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in Therapy, 25(8), 725–742. CrossRef
Schrezenmeier, H., Muus, P., Socié, G., et al. (2014). Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica, 99(5), 922–929. CrossRef
USFDA. (2009). US food and drug administration (FDA) guidance for industry -patient-reported outcome measures: Use in medical product development to support labeling claims. Maryland: USFDA.
Skevington, S., Lotfy, M., & O’Connell, K. (2004). The World Health Organization’s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. Quality of Life Research, 13(2), 299–310. CrossRef
McDowell, I. (2006). Measuring health: A guide to rating scales and questionnaires (3rd ed.). Oxford: Oxford University Press. CrossRef
Aaronson, N., Ahmedzai, S., Bergman, B., et al. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376. CrossRef
Luckett, T., King, M., Butow, P., et al. (2011). Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: Issues, evidence and recommendations. Annals of Oncology, 22(10), 2179–2190. CrossRef
Hullmann, S., Ryan, J., Ramsey, R., Chaney, J., Mullin, & sL (2011). Measures of general pediatric quality of life: Child Health Questionnaire (CHQ), DISABKIDS Chronic Generic Measure (DCGM), KINDL-R, Pediatric Quality of My Life Questionnaire (QoML). Arthritis Care & Research (Hoboken), 63(Supp11), S420–S430. CrossRef
Panepinto, J., O’Mahar, K., DeBaun, M., Rennie, K., & Scott, J. (2004). Validity of the child health questionnaire for use in children with sickle cell disease. Journal of Pediatric Hematology, 26(9), 574–578. CrossRef
Panepinto, J., Pajewski, N., Foerster, L., & Hoffmann, R. (2008). The performance of the PedsQL generic core scales in children with sickle cell disease. Journal of Pediatric Hematology, 30(9), 666–673. CrossRef
Panepinto, J., Torres, S., Bendo, C., et al. (2014). PedsQLTM Multidimensional Fatigue Scale in sickle cell disease: Feasibility, reliability, and validity. Pediatric Blood & Cancer, 61(1), 171–177. CrossRef
Tomlinson, D., Hinds, P., Ethier, M., Ness, K., Zupanec, S., & Sung, L. (2013). Psychometric properties of instruments used to measure fatigue in children and adolescents with cancer: A systematic review. Journal of Pain and Symptom Management, 45(1), 83–91. CrossRef
Lai, J., Cella, D., Kupst, M., et al. (2007). Measuring fatigue for children with cancer: Development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F). Journal of Pediatric Hematology, 29(7), 471–479. CrossRef
Panepinto, J., Torres, S., & Varni, J. (2012). Development of the PedsQLTM Sickle Cell Disease Module items: Qualitative methods. Quality of Life Research, 21(2), 341–357. CrossRef
Keller, S., Yang, M., Treadwell, M., Werner, E., & Hassell, K. (2014). Patient reports of health outcome for adults living with sickle cell disease: Development and testing of the ASCQ-Me item banks. Health and Quality of Life Outcomes, 12, 125–135. CrossRef
Golics, C., Basra, M., Finlay, A., & Salek, S. (2013). The development and validation of the Family Reported Outcome Measure (FROM-16)(©) to assess the impact of disease on the partner or family member. Quality of Life Research, 23(1), 317–326. CrossRef
Hand, C. (2016). Measuring health-related quality of life in adults with chronic conditions in primary care settings. Critical review of concepts and 3 tools. Canadian Family Physician, 62(7), e375–e383.
Grace, R., Bianchi, P., van Beers, E., et al. (2018). Clinical spectrum of pyruvate kinase deficiency: Data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 131(20), 2183–2192. CrossRef
- Appraisal of patient-reported outcome measures in analogous diseases and recommendations for use in phase II and III clinical trials of pyruvate kinase deficiency
M. S. Salek
J. R. Johns
E. N. Oliva
- Springer International Publishing